No Data
We Think That There Are More Issues For Shenzhen YHLO Biotech (SHSE:688575) Than Just Sluggish Earnings
Could The Market Be Wrong About Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575) Given Its Attractive Financial Prospects?
Third Quarter Report 2024
Yahui Long (688575.SH): net income was 0.219 billion yuan in the first three quarters, a year-on-year decrease of 23.29%.
On October 29, AHlLOnG (688575.SH) released its third quarter report for 2024, with the company's revenue for the first three quarters of the year at 1.394 billion yuan, a decrease of 9.78% year-on-year; net income attributable to shareholders of the listed company was 0.219 billion yuan, a decrease of 23.29% year-on-year; and basic earnings per share were 0.38 yuan.
Yahui Long (688575.SH): Net income in the first three quarters was 0.219 billion yuan, a 23.29% year-on-year decrease.
On October 29, Yahui Long (688575.SH) released its third-quarter report, with revenue of 1.39 billion yuan in the first three quarters, a year-on-year decrease of 9.78%, net income of 0.219 billion yuan, a year-on-year decrease of 23.29%, non-GAAP net income of 0.2 billion yuan, a year-on-year increase of 19.01%, and basic earnings per share of 0.38 yuan.
Yahui Long (688575.SH) has obtained a medical instruments registration certificate.
Yahui Long (688575.SH) announced that the company recently received a notice issued by the Guangdong Provincial Pharmaceutical Administration...
Shenzhen YHLO Biotech Co., Ltd.'s (SHSE:688575) Popularity With Investors Is Under Threat From OverpricingNo Data
No Data
